Boehringer and Prime Therapeutics enter deal to weigh total costs of Jardiance

7 years ago

by David Miller

958 Views

Written by David Miller

Under a new deal with Boehringer Ingelheim, Prime Therapeutics plans to examine the total healthcare costs for SGLT2 drug Jardiance versus the competition.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!